Thursday, 17 Aug 2017

You are here

US Drug Spending Will Rise Steadily Thru 2021

Reuters has reported that U.S.spending on prescription drugs in 2016 increased by 5.8 percent over 2015 levels to $450 billion based on list prices, and by 4.8 percent to $323 billion when adjusted for discounts and rebates.

A forecast from Quintiles/IMS indicates that the cost of prescription medicines in the United States will increase 4-7 percent through 2021, reaching nearly $600 billion.

QuintilesIMS (previously known as IMS) compiles data for the pharmaceutical industry, has reduced its projections due to fewer new medicines being approved in 2016.

Taking likely manufacturer discounts and rebates into account, spending would grow 2-5 percent to $375 billion to $405 billion in 2021, as net price increases for patent-protected branded drugs slows, the report said.

The rising cost of drugs is becoming a major issue with politicians and insurers, for both generic and branded medicines.

The number of new drug approvals by the FDA has declined to 22 new medicines in 2016, which is down from 45 in 2015, 

The projected estimates taking into account that new drug approvals will rebound in 2019 and after, as QuintilesIMS estimates 40 to 45 new brand launches per year through 2021.

 

Spending on pain medicines declined 1 percent, while prescription growth was seen with chronic therapies, such as those for hypertension and mental health.

  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Curbside Consults - July 2017

Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines. Here are four new cases. 

Drug Costs Vary by 600% in Different Countries

The Canadian Medical Association Journal has studied the costs of prescription drugs in 10 high-income countries (seven European countries, Australia, Canada and New Zealand) and found that many of these medicines varied by more than 600%.

ACR/AAHKS Guidelines on Perioperative Management

The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop consensus-based guidelines for perioperative management of antirheumatic therapies for patients with rheumatic diseases who plan to undergo total joint replacement.

20% Price Hike Among Pfizer Drugs

The increasing cost of drug has been the subject of concern and review - by legislators, reporters and patients.

The Financial Times has reviewed the annual price increases for the 91 drugs in Pfizers portfolio, showing an average price increase by 20 percent in the past year.

This includes Viagra and Lyrica.

Best to Rehab at Home Following Joint Replacement

New York Times article sheds light on recent evidence suggesting that those undergoing hip or knee replacement will do just as well with home therapy compared to inpatient rehabilitation following surgery.